Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses. Total revenue was slightly weak overall, but sales were stronger for two newly launched medicines — Leqembi and Skyclarys — that matter most to the biotech’s turnaround effort.
Shares rose 5% to $202 in early trading.
Here’s what you need to know from Biogen’s earnings and conference call:
Love is blind, the saying goes, and thanks to a world-first Australian study, we are now a step closer to understanding why.
The research team will employ computer simulations and experiments to allow companies to design and test IR tablets virtually. Credit: De Montfort University. A collaborative
PacBio today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S rRNA